Physician profile
Liangping Weng
NPI 1740433275
$10,239.94
in general payments reported to CMS, 2019-2025
62 companies · $1,824 in 2025
The $1,824 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,166 · 2021: $1,292 · 2022: $1,049 · 2023: $1,821 · 2024: $2,087 · 2025: $1,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,386 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,386.16 |
| Education | $345.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $884.69 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $618.86 | 2020-2025 | Darzalex, Tecvayli, Erleada |
| Incyte Corporation | $572.76 | 2020-2025 | Jakafi, Pemazyre, Monjuvi |
| Pfizer INC. | $515.97 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $512.00 | 2020-2025 | Opdivo, Opdualag, Augtyro |
| Glaxosmithkline, LLC. | $477.69 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Daiichi Sankyo INC. | $430.40 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $404.36 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $400.39 | 2020-2024 | |
| Abbvie INC. | $376.90 | 2020-2025 | Venclexta |
| Seagen INC. | $343.00 | 2020-2023 | Padcev, Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $339.50 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| Astellas Pharma US INC | $294.34 | 2021-2025 | Padcev, Xtandi |
| Rigel Pharmaceuticals, INC. | $241.69 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Gilead Sciences, INC. | $219.89 | 2021-2025 | Trodelvy |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liangping Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.